Cisneros Trigo, 2011 - Google Patents
Development of new inhibitors of the enzime monoacylglycerol lipase (MGL)Cisneros Trigo, 2011
View PDF- Document ID
- 6474533714569326277
- Author
- Cisneros Trigo J
- Publication year
External Links
Snippet
UNIVERSIDAD COMPLUTENSE DE MADRID DEVELOPMENT OF NEW INHIBITORS OF
THE ENZIME MONOACYLGLYCEROL LIPASE (MGL). Page 1 UNIVERSIDAD
COMPLUTENSE DE MADRID FACULTAD DE CIENCIAS QUÍMICAS Departamento de …
- 102000005398 Monoacylglycerol Lipase 0 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Piomelli et al. | N-acylethanolamine acid amidase (NAAA): structure, function, and inhibition | |
| Gil-Ordóñez et al. | Monoacylglycerol lipase (MAGL) as a promising therapeutic target | |
| Lambert et al. | The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications | |
| Tsuboi et al. | Endocannabinoids and related N-acylethanolamines: biological activities and metabolism | |
| Piomelli | The molecular logic of endocannabinoid signalling | |
| Bisogno et al. | Fatty acid amide hydrolase, an enzyme with many bioactive substrates. Possible therapeutic implications | |
| Marzo et al. | The endocannabinoid system and its therapeutic exploitation | |
| Bisogno et al. | The endocannabinoid signalling system: biochemical aspects | |
| Ahn et al. | Enzymatic pathways that regulate endocannabinoid signaling in the nervous system | |
| Haeggstrom et al. | Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease | |
| Basavarajappa | Critical enzymes involved in endocannabinoid metabolism | |
| Ueda et al. | Metabolism of endocannabinoids and related N‐acylethanolamines: Canonical and alternative pathways | |
| Rahman et al. | New players in the fatty acyl ethanolamide metabolism | |
| Bandiera et al. | Advances in the discovery of N-acylethanolamine acid amidase inhibitors | |
| Shayman et al. | Group XV phospholipase A2, a lysosomal phospholipase A2 | |
| Skácel et al. | Small molecule inhibitors targeting biosynthesis of ceramide, the central hub of the sphingolipid network | |
| Felder et al. | Cannabinoids biology: the search for new therapeutic targets | |
| KR20060006973A (en) | Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders | |
| Solorzano et al. | Synthesis and structure− activity relationships of N-(2-oxo-3-oxetanyl) amides as N-acylethanolamine-hydrolyzing acid amidase inhibitors | |
| CN104203906B (en) | Meta-Substituted Biphenyl Peripherally Restricted FAAH Inhibitors | |
| Cascio | PUFA-derived endocannabinoids: an overview | |
| Tai et al. | Endogenous molecules stimulating N-acylethanolamine-hydrolyzing acid amidase (NAAA) | |
| Piomelli | The endogenous cannabinoid system and the treatment of marijuana dependence | |
| Tsuboi et al. | Involvement of acid ceramidase in the degradation of bioactive N-acylethanolamines | |
| Jung et al. | Cannabinoids and endocannabinoids |